Xcout Intel
Slate Medicines
Slate Medicines is a privately held biotechnology company advancing next-generation therapeutics for headache treatment, with headquarters located in Raleigh, North Carolina and Boston, Massachusetts.
Subscribe to see Slate Medicines’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
Slate Medicines at a glance
Slate Medicines is a pharmaceuticals company headquartered in United States. Its most recent funding round, Series A, raised $130M in February 2026. Xcout tracks 18 named people at Slate Medicines, including Greg Oakes (CEO).
Slate Medicines leadership
- Greg OakesCEO
- Gregory OakesChief Executive Officer and Board Director
- Neil BuckleyCOO and president
- John Umstead, CPAChief Financial Officer
- Dr. Roger CadyChief Medical Officer
- Kenneth KoblanChief Scientific Officer
12 more named people on record for Slate Medicines, with roles, board committees and tenure — see the full roster →
Slate Medicines funding rounds
Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| Series A | $130M | 2 named |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Recent Slate Medicines news
Investors
Slate Medicines competitors
A few of Slate Medicines's closest competitors — see the full list of competitors and alternatives →
Epalex Corp. is a clinical-stage pharmaceutical company focused on developing breakthrough therapies for migraine and epilepsy, with its corporate headquarters in Mountain View, California.
Novilla Pharmaceuticals is a biotechnology company headquartered in Cambridge, Massachusetts, developing a novel class of localized medicines designed by AI to treat pain. The firm focuses on targeted therapeutics that function only where needed within the body. It operates as a privately held startup with a small scientific team.
Antares Therapeutics, Inc. is a biotechnology company headquartered in Boston, Massachusetts, focused on developing first-in-class precision medicines.
Mirata Pharmaceuticals, LLC develops non-addictive pain-relieving drugs as alternatives to prescription opioids. The company serves patients and physicians by creating medications that offer the analgesic benefits of opioids without their severe side effects and addictive properties.
IX Biopharma is a Singapore-based specialty pharmaceutical company developing and commercializing medicines using its WaferiX fast-dissolving sublingual wafer drug-delivery technology. It has focused particularly on pain-management and central-nervous-system products, serving patients and healthcare providers through pharmaceutical products such as Wafermine.
Scilex Holding Company operates as a biopharmaceutical firm primarily engaged in creating and distributing non-opioid treatments for individuals suffering from acute and chronic pain conditions. Its flagship product, ZTlido 1.8%, is a prescription-only topical lidocaine formulation designed to alleviate neuropathic pain, specifically that associated with post-herpetic neuralgia, a type of nerve pain occurring after a shingles infection. The company's development pipeline also features SP-102, known as SEMDEXA, a viscous corticosteroid gel administered via epidural injections. This candidate is currently in Phase 3 clinical trials, targeting lumbosacral radicular pain. Another investigational drug, SP-103, aims to treat low back pain and is progressing through Phase 2 clinical trials. Additionally, SP-104, an innovative low-dose, delayed-release naltrexone hydrochloride formulation, is in Phase 1 clinical development for managing fibromyalgia. Scilex Holding Company is headquartered in Palo Alto, California, and functions as a subsidiary of Sorrento Therapeutics, Inc.
Get Slate Medicines's news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on Slate Medicines in Xcout Intel
- 18 named people with titles, LinkedIn and board committees
- 1 funding round with the investors in each, and who they co-invest with
- 2 corporate events with sources — deals, leadership changes, layoffs
- The full competitor set, tracking, exports and API access